Literature DB >> 20660054

Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas.

Cosimo Durante1, Marco Attard, Massimo Torlontano, Giuseppe Ronga, Fabio Monzani, Giuseppe Costante, Marco Ferdeghini, Salvatore Tumino, Domenico Meringolo, Rocco Bruno, Giorgio De Toma, Umberto Crocetti, Teresa Montesano, Angela Dardano, Livia Lamartina, Adele Maniglia, Laura Giacomelli, Sebastiano Filetti.   

Abstract

CONTEXT: Most papillary thyroid microcarcinomas (PTMCs; ≤ 1 cm diameter) are indolent low-risk tumors, but some cases behave more aggressively. Controversies have thus arisen over the optimum postoperative surveillance of PTMC patients.
OBJECTIVES: We tested the hypothesis that clinical criteria could be used to identify PTMC patients with very low mortality/recurrence risks and attempted to define the best strategy for their management and long-term surveillance.
DESIGN: We retrospectively analyzed data from 312 consecutively diagnosed PTMC patients with T1N0M0 stage disease, no family history of thyroid cancer, no history of head-neck irradiation, unifocal PTMC, no extracapsular involvement, and classic papillary histotypes. Additional inclusion criteria were complete follow-up data from surgery to at least 5 yr after diagnosis. All 312 had undergone (near) total thyroidectomy [with radioactive iodine (RAI) remnant ablation in 137 (44%) - RAI group] and were followed up yearly with cervical ultrasonography and serum thyroglobulin, TSH, and thyroglobulin antibody assays.
RESULTS: During follow-up (5-23 yr, median 6.7 yr), there were no deaths due to thyroid cancer or reoperations. The first (6-12 months after surgery) and last postoperative cervical sonograms were negative in all cases. Final serum thyroglobulin levels were undetectable (<1 ng/ml) in all RAI patients and almost all (93%) of non-RAI patients.
CONCLUSION: Accurate risk stratification can allow safe follow-up of most PTMC patients with a less intensive, more cost-effective protocol. Cervical ultrasonography is the mainstay of this protocol, and negative findings at the first postoperative examination are highly predictive of positive outcomes.

Entities:  

Mesh:

Year:  2010        PMID: 20660054     DOI: 10.1210/jc.2010-0762

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

1.  Usefulness of thyroglobulin measurement in needle washouts of fine-needle aspiration biopsy for the diagnosis of cervical lymph node metastases from papillary thyroid cancer before thyroidectomy.

Authors:  Dae-Weung Kim; Se Jeong Jeon; Chang Guhn Kim
Journal:  Endocrine       Date:  2012-02-18       Impact factor: 3.633

2.  BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study.

Authors:  Giovanni Tallini; Dario de Biase; Cosimo Durante; Giorgia Acquaviva; Michele Bisceglia; Rocco Bruno; Maria Letizia Bacchi Reggiani; Gian Piero Casadei; Giuseppe Costante; Nadia Cremonini; Livia Lamartina; Domenico Meringolo; Francesco Nardi; Annalisa Pession; Kerry J Rhoden; Giuseppe Ronga; Massimo Torlontano; Antonella Verrienti; Michela Visani; Sebastiano Filetti
Journal:  Mod Pathol       Date:  2015-08-14       Impact factor: 7.842

3.  Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.

Authors:  Aubrey A Carhill; Danielle R Litofsky; Douglas S Ross; Jacqueline Jonklaas; David S Cooper; James D Brierley; Paul W Ladenson; Kenneth B Ain; Henry G Fein; Bryan R Haugen; James Magner; Monica C Skarulis; David L Steward; Mingxhao Xing; Harry R Maxon; Steven I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

Review 4.  Post-treatment surveillance of thyroid cancer.

Authors:  L Y Wang; I Ganly
Journal:  Eur J Surg Oncol       Date:  2017-07-19       Impact factor: 4.424

5.  SERIAL NECK ULTRASOUND IS MORE LIKELY TO IDENTIFY FALSE-POSITIVE ABNORMALITIES THAN CLINICALLY SIGNIFICANT DISEASE IN LOW-RISK PAPILLARY THYROID CANCER PATIENTS.

Authors:  Samantha Peiling Yang; Ariadne M Bach; R Michael Tuttle; Stephanie A Fish
Journal:  Endocr Pract       Date:  2015-09-15       Impact factor: 3.443

6.  Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer.

Authors:  Martina Rossi; Mattia Buratto; Federico Tagliati; Roberta Rossi; Sabrina Lupo; Giorgio Trasforini; Giovanni Lanza; Paola Franceschetti; Stefania Bruni; Ettore Degli Uberti; Maria Chiara Zatelli
Journal:  Thyroid       Date:  2014-11-24       Impact factor: 6.568

7.  Variation in the management of thyroid cancer.

Authors:  Megan R Haymart; Mousumi Banerjee; Di Yang; Andrew K Stewart; James C Sisson; Ronald J Koenig; Gerard M Doherty; Jennifer J Griggs
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

Review 8.  Value of ¹³¹I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature.

Authors:  Yan-Li Xue; Zhong-Ling Qiu; Hong-Jun Song; Quan-Yong Luo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-15       Impact factor: 9.236

9.  Cost-effectiveness analysis of papillary thyroid cancer surveillance.

Authors:  Laura Y Wang; Benjamin R Roman; Jocelyn C Migliacci; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Cancer       Date:  2015-08-17       Impact factor: 6.860

10.  Effectiveness of routine ultrasonographic surveillance of patients with low-risk papillary carcinoma of the thyroid.

Authors:  Laura Y Wang; Benjamin R Roman; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Surgery       Date:  2015-12-31       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.